Breast cancer in young women: a rising threat: A 5-year follow-up comparative study

Abstract

Introduction: Breast cancer in young women is usually considered as breast cancer occurring in women younger than 40 years and is the most frequent cancer-related cause of death in these patients. In the past few years, there seems to be an increasing trend in the prevalence of breast cancer in young women, which, associated with poorer prognosis, more aggressive histologic features, and more frequent recurrence rates, makes it a rising threat to young women. This study aimed to evaluate the biological behavior of breast cancer in young women in our institution.Material and methods: A retrospective, unicentric, cohort study was conducted between 2012 and 2016. All consecutive patients with breast cancer were enrolled in the study. Cases were divided into two groups: case group, those younger than 40 years, and control group, those 40 years or older. The exclusion criterion was nonoperative treatment. Several clinical and pathologic parameters were evaluated, as well as were overall survival time and disease-free survival time.Results: The incidence of breast cancer in young women presented a rising tendency over the study period. Significant differences were observed in the comparison of the groups according to body mass index, age at menarche, age at birth of the first child, and proliferation rate. There were no differences in overall survival and disease-free survival rates between the groups.Conclusions: Young women had a more symptomatic presentation, a greater tumor proliferation rate, but similar outcomes compared with older patients. Greater multicentric studies are needed to confirm or refute these results.

LINC00525 enhances ZNF460-regulated CD24 expression through the sponge miR-125a-5p to promote malignant progression of breast cancer

“…Breast cancer (BC) is the most common malignancy in women worldwide, accounting for 30% of all female cancer cases and 15% of all female cancer deaths, and is the leading cause of cancer death in women (Sung et al 2021 ; Siegel et al 2023 ). Although there have been some advances in the early diagnosis, surgical treatment, endocrine therapy, radiotherapy, chemotherapy and targeted therapy of BC in the past few decades, there are still many patients facing the threat of recurrence and death (Fernandes et al 2023 ). Therefore, it is of great significance to explore the molecular mechanism of BC occurrence and development and to screen new diagnostic and therapeutic targets.…”

Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity

“…At the same time, although the prevalence of BC in Kazakhstan shows a steady upward trend in the age range from 42.5 years to 62.5 years, the prevalence of BC in young women has also increased from 309 cases in 2017 to 330 cases in 2021 [ 1 ]. Thus, combined with a poorer prognosis, more aggressive histologic features, and more frequent recurrences [ 3 , 4 ], BC in young Kazakh women in Kazakhstan is a growing threat. The problem is exacerbated by the fact that unlike an effective golden standard of mammography screening for women aged 40–70 years, screening programs for BC in young women are still underdeveloped in Kazakhstan.…”